The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 06, 2021

Filed:

Apr. 18, 2017
Applicant:

Amgen Research (Munich) Gmbh, Munich, DE;

Inventors:

Gerhard Zugmaier, Munich, DE;

Peter Kufer, Munich, DE;

Roman Kischel, Munich, DE;

Marion Subklewe, Munich, DE;

Christina Heitmueller, Munich, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/02 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2809 (2013.01); A61P 35/02 (2018.01); C07K 16/2803 (2013.01); C07K 16/2896 (2013.01); C07K 16/3061 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01); C07K 2317/32 (2013.01); C07K 2317/622 (2013.01); C07K 2317/90 (2013.01);
Abstract

The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.


Find Patent Forward Citations

Loading…